Editorial: Will Next Anti-Aging Market Disruptor Be Anti-Anti-Aging?
This article was originally published in The Rose Sheet
"The Rose Sheet" makes a case for the theoretical Dollar Anti-Aging Club and why updating the FDCA's "cosmetic" definition as part of broader regulatory reform could be in industry's interest.
You may also be interested in...
Firms marketing cosmetics with drug-like properties could be targeted increasingly by suits requiring courts, and even juries, to interpret their regulatory status if the Supreme Court's decision not to hear Athena Cosmetics v. Allergan is seen as an invitation by consumers and the plaintiffs' bar.
Following the recommendation of Solicitor General Donald Verrilli, the Supreme Court has declined to review Allergan v. Athena Cosmetics, a case examining if the Federal Food, Drug and Cosmetic Act preempts an unfair competition claim in California characterizing Athena's RevitaLash products as unapproved drugs. Athena predicts a "torrent of novel and disruptive litigation" could ensue.
While upstarts like Dollar Shave Club are touting value over tech innovation, P&G's Gillette is making efforts to educate dermatologists and consumers on the virtues of its latest razor designs. The brand's senior manager for scientific communications spoke with "The Rose Sheet" about the challenges involved in that work and offered insight into a recent underarm-malodor study that could be used to promote its Gillette Body razor for hair removal below the neck.